Literature DB >> 7365273

Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins.

N S Taylor, J G Bartlett.   

Abstract

Cholestyramine and colestipol were tested for binding of Clostridium difficile cytotoxin with use of batch absorption and column chromatography. The toxin was bound by both resins and could not be eluted from cholestyramine with either an ionic of a pH gradient. Vancomycin bound to cholestyramine more strongly than to colestipol. Cholestyramine and vancomycin were also tested for therapeutic efficacy in the hamster model of clindamycin-induced cecitis. Both compounds delayed death and reduced levels of cytotoxin in stool; these effects were greatest for vancomycin. Use of the two compounds in combination reduced concentrations of biologically active vancomycin in stool, but the levels still exceeded the minimum inhibitory concentration for C. difficile. These data suggest that the therapeutic benefit of cholestyramine in some patients with antibiotic-associated pseudomembranous colitis is due to its binding of the C. difficile cytotoxin. Since anion-exchange resins also bind vancomycin, caution is necessary if resins are used concurrently with vancomycin for therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7365273     DOI: 10.1093/infdis/141.1.92

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Clarification of article on Clostridium difficile--associated colitis.

Authors:  Kenneth Brown
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

4.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A.

Authors:  S O Vargas; D Horensky; A B Onderdonk
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

Review 6.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

7.  Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

Authors:  William Braunlin; Qiuwei Xu; Patrick Hook; Richard Fitzpatrick; Jeffrey D Klinger; Robert Burrier; Caroline B Kurtz
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

Review 8.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

9.  Metabolism of bile salts in mice influences spore germination in Clostridium difficile.

Authors:  Jennifer L Giel; Joseph A Sorg; Abraham L Sonenshein; Jun Zhu
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.